In the portfolio
IQV · IQVIA Holdings Inc.
Updated ·
Against its published line
Above its line on the last close.
How to read this
The red mark is the published kill line — the price that would prove the thesis wrong. The dot is where the name closed on 30 October 2026; a dot left of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row reads well clear, with a hollow dot to show the figure is off the drawn scale. Rows run tightest first.
Kill line
A daily close below $240, which would give back most of the gain since the late-July report; or a 2027 outlook at the 1 December 2026 investor day pointing to revenue growth below the 6.4%–7.3% guided for 2026.
Open pick Medium conviction, opened at $260.68. Since then +4.3% against the S&P 500's −5.5% (+9.8 pp). Kill line at open: $240.00 (daily close); graded by at the latest.
In the portfolio Since : −2.2%. See the portfolio.
Catalyst (in 24 days)
How picks are graded →The thesis
IQVIA's clinical-research bookings are growing faster than its revenue, which gives the shares modestly better-than-even odds of beating the S&P 500 over the next three months. The 1 December 2026 investor day decides the case, because management will give a broad framework for 2027 there, ahead of detailed guidance in February.
Third-quarter 2026 bookings rose 15% at a 1.2x book-to-bill ratio, and guidance went up on 27 October 2026. Company news shows no results, guidance change or broker action since 29 October 2026. The shares have drifted lower on no new business fact, closing at $264.88 on 5 November 2026, against $267.33 on 30 October 2026 and $271.55 on the 27 October 2026 report day, in split- and dividend-adjusted daily closes.
The narrative is maturing: the recovery has been widely covered since CNBC's 22 October 2026 segment "Josh's Best Stocks In The Market: IQVIA", and the last broker target change in Benzinga and fiscal.ai reports came on 29 October 2026. Peer reports from ICON, Medpace and Fortrea in late October show firm demand and uneven conversion into revenue.
Bullish and bearish views on IQVIA Holdings Inc.
The bull case on IQVIA Holdings Inc. (IQV), in brief: Trailing twelve-month bookings reached $11.7 billion, up 14%. The bear case: Backlog was cut by $2.1 billion.
Bull case
- Trailing twelve-month bookings reached $11.7 billion, up 14%.
- Guidance went up again. On 27 October 2026 IQVIA raised 2026 revenue guidance to $17,350–$17,500 million from $17,275–$17,475 million. It set adjusted EBITDA (earnings before interest, taxes, depreciation and amortisation) at $4,025–$4,055 million and adjusted earnings per share (EPS) at $12.90–$13.00.
- The quarter beat estimates. Adjusted EPS of $3.34 beat the $3.27 consensus and revenue of $4,428 million beat the $4,366 million consensus, per Benzinga on 27 October 2026. Revenue rose 8.0% as reported and 8.6% at constant currency.
- More backlog converts next year. IQVIA expects about $9.4 billion of R&D Solutions backlog to become revenue over the next twelve months, up 10%, per the 27 October 2026 release.
- Peers report rising awards. ICON reported a 1.56x net book-to-bill on 27 October 2026. Medpace reported record net new awards of $873.4 million against $789.6 million a year earlier on 21 October 2026, and Fortrea reported a 1.12x book-to-bill on 29 October 2026, per their releases.
- Demand indicators are rising. On the 27 October 2026 call, management said request-for-proposal flow rose by a high-single-digit percentage and clinical win rates rose 2 to 3 points. It put emerging biopharma funding at $90 billion so far in 2026, up more than 85%.
- Broker targets sit above the shares. After the report, Truist moved to $346, Baird to $328, JPMorgan to $325, Evercore ISI to $310 and TD Cowen to $307, per Benzinga on 28 October 2026 and 29 October 2026. Rothschild & Co Redburn's $299, reported by fiscal.ai on 28 October 2026, was the lowest of that group.
Bear case
- Backlog was cut by $2.1 billion. Contracted R&D Solutions backlog was $32.6 billion at 30 September 2026, after IQVIA removed about $2.1 billion of trials inactive for 18 months or more. The company says the cut does not affect guidance, bookings or next-twelve-month revenue from backlog.
- Acquisitions lift the guided growth. Updated 2026 guidance assumes acquisitions add 2 to 2.5 percentage points of growth, per coverage of the 27 October 2026 call. That raises the bar for the 2027 framework, which has to show demand-driven growth as well as acquired growth.
- Peers show slow conversion. ICON's third-quarter revenue of $2,024.8 million fell 2.9% despite its strong bookings, per its 27 October 2026 release. Medpace left its 2026 revenue midpoint at $2.845 billion, and coverage of its October call said slower backlog conversion is holding back fourth-quarter sales.
- Fourth-quarter comparisons are hard. Management called fourth-quarter bookings comparisons very difficult on the 27 October 2026 call. Commercial Solutions, which grew 6.9% to $1,789 million in the third quarter, mostly sits outside backlog, so the bookings gain says little about that segment.
- Adjusted figures flatter the earnings. Third-quarter GAAP diluted EPS was $2.10 against adjusted EPS of $3.34, per the 8-K. MarketBeat showed a price-to-earnings ratio of 34.29 on 28 October 2026, when the shares traded at $276.73.
- Debt is significant. Net leverage was 3.45x net debt to trailing adjusted EBITDA at 30 September 2026, per the 8-K.
Price setup
The $264.88 close on 5 November 2026 is 5.2% below the $279.36 52-week high and 9.5% above the level of three months earlier. The shares reached $275.06 on 29 October 2026 and have since given back the whole post-report gain. The 14-day relative strength index was 48.2 on 5 November 2026, a mid-range reading that shows no overheating.
MarketBeat listed the 50-day moving average at $264.74 and the 200-day at $209.94 on 28 October 2026, so the shares sit on the shorter average and well above the longer one. The $240 invalidation level is under the current price by a wide margin. MarketBeat's consensus target was $285.35 on 28 October 2026.
Crowding evidence is moderate. Retail attention rose with the 22 October 2026 CNBC segment. MarketBeat counted 10,023 insider shares sold for $2,413,394 in the three months to 28 October 2026, including W Richard Staub's 5,500 shares at about $232.68 on 3 August 2026. Those sales are small against insiders' 1.70% ownership, and IQVIA was retiring stock, with $950 million of buybacks in the first nine months of 2026.
Catalysts, next 30 days
- 1 December 2026: investor day. Senior management presents from 9:00 a.m. ET to about 12:30 p.m. ET, per the Q3 release, with a broad framework for 2027. It shows whether two quarters of 1.2x book-to-bill point to revenue growth above the 6.4%–7.3% guided for 2026.
- ~2027-02, est.: fourth-quarter 2026 results and detailed 2027 guidance. This falls outside the 30-day window and matters because it tests bookings against the hard comparison and sets the 2027 revenue and EPS targets.
What would change the view
The case breaks if the 1 December 2026 framework points to 2027 revenue growth below the 6.4%–7.3% guided for 2026. A second backlog adjustment, or management citing cancellations above the historical range, would undercut the bookings evidence. A fourth-quarter book-to-bill under 1.0x would end the claim that bookings are outrunning revenue.
On price, a daily close below $240 would give back most of the gain since the late-July report and invalidate the thesis.
What it trades with
The shares share their main drivers with ICON, Medpace and Fortrea: biotech funding, trial starts and the pace at which backlog becomes revenue. All four reported third-quarter bookings in the same October window, so a peer's fourth-quarter report is a direct read on IQVIA's conversion question. That link would weaken if ICON again reports falling revenue on a book-to-bill above 1.0x while IQVIA's revenue growth accelerates.
Commercial Solutions, the data and analytics segment, depends on pharma commercial spending more than on trial funding. It gives IQVIA a second driver that its pure clinical-research peers lack.
Notes
- IQVIA reports adjusted EPS that excludes acquisition amortisation and other items; in Q3 2026 GAAP diluted EPS was $2.10 against adjusted EPS of $3.34.
- IQVIA carries significant debt; net leverage was 3.45x net debt to trailing adjusted EBITDA at 30 September 2026, per the company's 8-K.
- IQVIA's R&D Solutions revenue includes reimbursed pass-through expenses; Q3 2026 segment growth was 8.7% reported and 6.8% excluding them.
- IQVIA's reported backlog counts contracted work only; trials removed as inactive are re-added if they resume but are not counted as new bookings.
- IQVIA pays no common dividend; it returns capital through share buybacks, $950M in the first nine months of 2026.
Sources
- IQVIA HOLDINGS INC. - Form 8-K - FY2026 · sec.gov
- Earnings call transcript: IQVIA tops Q3 2026 estimates and raises outlook By Investing.com · investing.com
- finance.yahoo.com
- Free Trial · marketbeat.com ·
- iqvia nyseiqv insider w richard staub sells 5500 shares 2026 08 04 · marketbeat.com ·
- Medpace Holdings, Inc. - Form 8-K - FY2026 · sec.gov ·
- Medpace (MEDP) Q3 2026 earnings review · finsee.ai
- Sustained commercial momentum, continued margin improvement, and targeted investments strengthen growth foundation · finviz.com